Je was op zoek naar: multicenter (Zweeds - Engels)

design: global multicenter, öppen
design: global multicentre, open-label

design: randomiserad, global multicenter, öppen
design: randomised, global multicentre, open-label

design: randomiserad, global multicenter, dubbelblind, regimkontrollerad
design: randomised, global multicentre, double-blind, regimen-controlled

np-c registret är en multicenter, prospektiv observations, kohortstudie
the np-c registry is a multicentre, prospective, observational, cohort study in patients diagnosed with niemann- pick type c (np-c) disease.

effekten av infliximab utvärderades i två multicenter -, randomiserade och dubbelblinda studier:
the efficacy of infliximab was assessed in two multicenter, randomised, double blind studies:

f avsikten med den tredje studien, som var multicenter, dubbelblind, och randomiserad, var att
there were no clinically relevant changes in the laboratory values or vital signs in either treatment group throughout the clinical trial.

l sä avsikten med den tredje studien, som var multicenter, dubbelblind, och randomiserad, var att
or the purpose of the third multicentre, double-blind, randomised study was the assessment of efficacy

0,075 mg/kg två gånger dagligen i en 21 dagar lång öppen, multicenter, dosintervallstudie.
0.10 or 0.15 mg/kg teduglutide once daily, or 0.05 or 0.075 mg/kg bid in a 21-day open-label, multicenter, dose-ranging study.

immunogenicitetsdata för prevenar har studerats i en öppen, multicenter studie på 49 barn med sickle- cell anemi.
the immunogenicity of prevenar has been investigated in an open-label, multicenter study in 49 infants with sickle cell disease.

effekten av infliximab utvärderades i två multicenter-, randomiserade och dubbelblinda studier: spirit och express.
the efficacy of infliximab was assessed in two multicenter, randomised, double-blind studies: spirit and express.

effekten med infliximab utvärderades i två multicenter, randomiserade, dubbelblinda, pivotala studier: attract och aspire.
the efficacy of infliximab was assessed in two multicentre, randomised, double-blind, pivotal clinical studies: attract and aspire.

lal-cl02 var en multicenter-, dubbelblind, placebokontrollerad studie av 66 barn och vuxna med lal-brist.
lal-cl02 was a multicentre, double-blind, placebo-controlled study in 66 children and adults with lal deficiency.

totalt 51 barn med nyligen diagnosticerad och obehandlad kml i kronisk fas har enrollerats i en öppen, multicenter, enkelarmad fas ii-studie.
a total of 51 paediatric patients with newly diagnosed and untreated cml in chronic phase have been enrolled in an open-label, multicentre, single-arm phase ii trial.

design: randomiserad, global multicenter, dubbelblind, placebokontrollerad behandling: viekirax och dasabuvir med viktbaserad ribavirin i 12 veckor
design: randomised, global multicentre, double-blind, placebo-controlled treatment: viekirax and dasabuvir with weight-based ribavirin for 12 weeks

två randomiserade, multicenter, dubbelblinda, placebo-kontrollerade fas-iii-studier utfördes på patienter med cervikal dystoni.
two phase iii randomised, multicentre, double-blind, placebo-controlled studies were conducted in patients with cervical dystonia.

den dubbla studien av icke nukleosidanaloger 2 nn, var en randomiserad, öppen, multicenter, prospektiv studie som jämförde nnrti nevirapin, efavirenz och båda läkemedlen tillsammans.
the double non-nucleoside study 2 nn was a randomised, open-label, multicentre prospective study comparing the nnrtis nevirapine, efavirenz and both medicinal products given together.

en stor, internationell, öppen, multicenter, randomiserad fas iii-studie har genomförts på patienter med nyligen diagnostiserad (ph+)-kml.
one large, open-label, multicentre, international randomised phase iii study has been conducted in patients with newly diagnosed ph+ cml.

kliniska studier vid hes/ cel en öppen, multicenter, fas- ii klinisk studie (studie b2225) som testade glivec hos olika populationer
clinical studies in hes/ cel one open-label, multicentre, phase ii clinical trial (study b2225) was conducted testing glivec in diverse populations of patients suffering from life-threatening diseases associated with abl, kit or pdgfr protein tyrosine kinases.

effekt och säkerhet undersöktes i två multicenter, randomiserade, dubbel-blinda, upprepade parallellgruppstudier: re-cover och re-cover ii.
the efficacy and safety was investigated in two multi-center, randomised, double blind, parallel- group, replicate studies re-cover and re-cover ii.

active-a-studien (n = 7554) var en multicenter, randomiserad, dubbelblind, placebokontrollerad studie som jämförde klopidogrel 75 mg/dag + asa (n = 3772) med placebo + asa (n = 3782).
the active-a study (n=7,554) was a multicenter, randomized, double-blind, placebo-controlled study which compared clopidogrel 75 mg/day + asa (n=3,772) to placebo + asa (n=3,782).